<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02968680</url>
  </required_header>
  <id_info>
    <org_study_id>10M-15-3</org_study_id>
    <secondary_id>NCI-2016-01088</secondary_id>
    <secondary_id>10M-15-3</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT02968680</nct_id>
  </id_info>
  <brief_title>Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma</brief_title>
  <official_title>Pilot Translational Study of Sonazoid-Enhanced Ultrasonography for Sentinel Lymph Node Mapping in Cutaneous Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot phase I trial studies how well sonazoid-enhanced ultrasound works in detecting
      sentinel lymph node in patients with cutaneous melanoma. Sonazoid is a contrast agent that
      may make it easier to see if the tumor cells have spread to the sentinel lymph node using an
      ultrasound.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To study the imaging feasibility of peri-tumoral administration of sonazoid ultrasound
      contrast agent for assessment of sentinel lymph node (SLN) detection in melanoma.

      II. To compare SLN detection between sonazoid ultrasound and standard of care (SOC)
      technique.

      SECONDARY OBJECTIVES:

      I. To assess the sonazoid ultrasound (US) imaging appearance of lymph nodes which are shown
      to be involved with metastatic disease.

      OUTLINE:

      Patients receive sonazoid intradermally (ID) and undergo ultrasound imaging. Patients also
      undergo standard of care sentinel lymph node biopsy (SLNB).

      After completion of study treatment, patients are followed up at 24 and 48 hours.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2017</start_date>
  <completion_date type="Anticipated">April 26, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients with SLN identified by sonazoid-US alone or both sonazoid-US and conventional methods</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Analyzed using descriptive comparison.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cutaneous Melanoma</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (sonazoid, ultrasound imaging, SLNB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sonazoid ID and undergo ultrasound imaging. Patients also undergo standard of care SLNB.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel Lymph Node Biopsy</intervention_name>
    <description>Undergo SLNB</description>
    <arm_group_label>Diagnostic (sonazoid, ultrasound imaging, SLNB)</arm_group_label>
    <other_name>Sentinel Node Biopsy</other_name>
    <other_name>Sentinel node biopsy alone</other_name>
    <other_name>SLNB</other_name>
    <other_name>SNB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasonography</intervention_name>
    <description>Undergo sonazoid-enhanced ultrasonography</description>
    <arm_group_label>Diagnostic (sonazoid, ultrasound imaging, SLNB)</arm_group_label>
    <other_name>ULTRASOUND</other_name>
    <other_name>Ultrasound Imaging</other_name>
    <other_name>Ultrasound Test</other_name>
    <other_name>Ultrasound, Medical</other_name>
    <other_name>US</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sonazoid</intervention_name>
    <description>Patients receive sonazoid intradermally (ID) and undergo ultrasound imaging.</description>
    <arm_group_label>Diagnostic (sonazoid, ultrasound imaging, SLNB)</arm_group_label>
    <other_name>Contrast ultrasound microvascular perfusion imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cutaneous melanoma with Breslow depth &gt; 1 mm or melanoma Breslow depth of 0.76 - 1.00
             mm in setting of ulceration, extensive regression

          -  Mitotic rate &gt;= 1/mm^2

          -  Presence of angiolymphatic invasion

          -  Deep positive margin

          -  No known allergies to contrast material

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Patients with known cardiac shunt

          -  Patients with class II heart failure or worse, per New York Heart Association (NYHA)
             classification

          -  Patients who have experienced an acute coronary syndrome or angina in the past 6
             months

          -  Patients who have undergone coronary artery bypass grafting (CABG) or coronary
             stenting in the past 3 years

          -  Patients with evidence of moderate or severe cardiac valvular disease on
             echocardiogram

          -  Patients with evidence of moderate or severe pulmonary hypertension on echocardiogram

          -  Patients with stage II chronic obstructive pulmonary disease (COPD) or worse, per
             Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification

          -  Patients with hypersensitivity to sonazoid or one of its components

          -  Patients with hypersensitivity to egg or egg products, because sonazoid contains a
             chicken egg-derived surfactant (hydrogenated egg phosphatidylserine sodium)

          -  Patients who cannot consent for themselves
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin King, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosaura Diaz</last_name>
    <phone>323-442-7469</phone>
    <email>Rosaura.diaz@med.usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bhushan Desai</last_name>
    <phone>323-442-7469</phone>
    <email>Bhushan.Desai@med.usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosaura Diaz</last_name>
      <phone>323-442-7469</phone>
      <email>Rosaura.diaz@med.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bhushan Desai</last_name>
      <phone>323-442-7469</phone>
      <email>Bhushan.Desai@med.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin King, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

